• Economy
  • Investing
Long Distance Investing
  • Stock
  • Editor’s Pick
Investing

Tilray secures new cannabis cultivation license in Germany: Is it time to buy TLRY?

by July 22, 2024
written by July 22, 2024

Tilray Brands Inc (NASDAQ: TLRY) has made a significant stride in its European operations by securing a new cannabis cultivation license in Germany. 

This development, under the country’s new Cannabis Act (MedCanG), is set to substantially boost the production capacity of Tilray’s Aphria RX GmbH facility in Berlin. 

This news comes at a crucial time for the New York-based firm, which has seen its stock decline by 35% since early April.

What the new license means for Tilray stock

The new license is expected to increase Tilray’s production of medical cannabis by up to fivefold, according to the company’s press release on Monday. 

This expansion is a pivotal move for Tilray, potentially aiding in the recovery of its stock. The license also allows Tilray to cultivate and produce up to 31 approved strains of cannabis, a significant increase from the previous limit of three strains. 

This will not only enhance the genetic diversity of Tilray’s products but also expand its product range in Germany’s medical cannabis market.

Denise Faltischek, Tilray’s Chief Strategy Officer, highlighted the importance of the new license, stating it will enable “greater access to some of the highest quality medical cannabis produced in Germany.” 

This development underscores Tilray’s commitment to expanding its footprint in the European market and positions the company to capitalize on Germany’s growing medical cannabis industry.

Positive market response and strategic importance

Investors have responded positively to the news, with Tilray’s stock rising approximately 3% at the time of writing on Monday. 

This uptick reflects investor confidence in the company’s strategic moves to strengthen its presence in Europe and enhance its production capabilities.

The new license comes at a critical juncture for Tilray, as the company is set to report its second-quarter earnings on July 29th. 

The timing of this announcement could provide a much-needed boost in investor sentiment ahead of the earnings report. In 2019, the German Federal Institute for Drugs and Medical Devices (BfArM) granted Aphria RX the most comprehensive permit for the cultivation of medical cannabis. 

The new Cannabis Act has significantly increased the use of medical cannabis in Germany, and Tilray is now well-positioned to fully capitalize on this market opportunity with its new license.

Financial outlook and market expectations

Tilray’s recent financial performance has been mixed. The company broke even on a per-share basis in the fourth quarter of 2023 but is expected to report a loss of 2 cents per share in the upcoming fourth quarter.

Investors will be closely watching for updates on Tilray’s outlook for free cash flow, which management previously indicated is unlikely to turn positive in 2024.

Earlier in July, analysts at Zuanic & Associates assumed coverage of Tilray stock with a “neutral” rating.

They cited the company’s potential to benefit from regulatory updates in overseas medical markets as a key factor. This new license in Germany could be a catalyst for Tilray to leverage these regulatory changes and improve its financial performance.

Tilray’s acquisition of a new cannabis cultivation license in Germany marks a significant step in the company’s strategic expansion in Europe. 

The anticipated increase in production capacity and product diversity positions Tilray to capitalize on Germany’s growing medical cannabis market. 

As the company prepares to report its second-quarter earnings, this development could help restore investor confidence and pave the way for future growth.

Watch here: https://www.youtube.com/embed/0UUrKOz49MA?feature=oembed

The post Tilray secures new cannabis cultivation license in Germany: Is it time to buy TLRY? appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Joe Biden Drop Out: US Election 2024 Updates
next post
Federal Reserve fines Walmart-linked Green Dot Corp $44 million after customers lost access to funds

You may also like

MEXC strengthens reserve backing with $390M asset increase

April 23, 2025

Oil prices rebound: what’s driving the rally and...

April 23, 2025

Silver rises with gold, but industrial demand outlook...

April 23, 2025

Lead Edge Capital founder Mitchell Green says recession...

April 23, 2025

Why is Toncoin price rising today?

April 23, 2025

BC.GAME to host ‘Untamed Arena’ during TOKEN2049 Dubai,...

April 23, 2025

Keycard launches pre-sale for Shell: the most open,...

April 23, 2025

BA stock rises as Boeing reports smaller Q1...

April 23, 2025

US stocks surge at open: Dow climbs 2.4%,...

April 23, 2025

iExec launches 1M $RLC fund to support AI...

April 23, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Krispy Kreme stock plunges after doughnut chain pauses McDonald’s rollout, pulls outlook

      May 8, 2025
    • UnitedHealthcare sued by shareholders over reaction to CEO’s killing

      May 8, 2025
    • Semtech Showcases Next-Gen LoRa® Technology at IoT Solutions World Congress 2025

      May 8, 2025
    • AMD CEO calls China a ‘large opportunity’ and warns against strict U.S. chip controls

      May 7, 2025

    Categories

    • Economy (679)
    • Editor's Pick (348)
    • Investing (4,555)
    • Stock (820)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: Longdistanceinvestings.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 Longdistanceinvestings.com

    Long Distance Investing
    • Economy
    • Investing
    Long Distance Investing
    • Stock
    • Editor’s Pick